ArticleBMC complementary medicine and therapies2025
Exploring the effect of Huangqi Fuling Decoction on gastric cancer based on UPLC-MS, network pharmacology and experiments in vitro.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inflammation-Driven JNK Activation Promotes EMT and Metastasis in Gastric Cancer and Is Attenuated by Huangjin Shuangshen Granules.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHuangqi Fuling Decoction (HQFLT) is a traditional Chinese medicine prescription that is applied to treat a variety of diseases. However, the mechanism of HQFLT in the treatment of gastric cancer is still unclear, which hinders its clinical application.
methodsComponents and targets of HQFLT were collected from TCMSP, TCMID and ETCM databases, and potential targets of gastric cancer were collected from GEO database. The intersection targets of component disease were imported into STRING database to construct protein-protein interaction network, and the intersection targets were analyzed by GO and KEGG to explore the involved biological processes. The network topology analysis of intersection targets was carried out using Cytoscape software, and hub genes were selected according to the degree value. To further identify the main active components of HQFLT, we used UPLC-MS/MS techniques for analysis and intersected with network pharmacological results to obtain the most critical components. Molecular docking techniques were used to calculate the binding energy of intersection components and hub genes. Regarding cell experiments, the effect of HQFLT on the viability of gastric cancer cells was detected by CCK-8 assay, and the effect of HQFLT on cell proliferation was verified by flow cytometry and colony formation assay. The transwell experiment was conducted to investigate the effect of HQFLT on tumor metastasis. qRT-PCR and Western blot were used to detect the regulatory effects of HQFLT on hub genes and key signaling pathways.
resultsA total of 189 active components, and 278 targets of HQFLT and 1817 targets of gastric cancer were obtained by network pharmacology. A total of 51 intersection targets were screened by Venny method. These targets were mainly involved in signal transduction, apoptosis regulation and angiogenesis, and may be involved in the regulation of MAPK signaling pathway. A total of 5 hub genes were obtained after degree screening by Cytoscape, namely IL6, PTGS2, ICAM1, VCAMI and CCL2, which showed significant differences in clinical staging, molecular typing and survival prognosis. After the intersection of 44 components obtained from UPLC-MS and network pharmacology, Calycosin was obtained. The results of molecular docking showed that the compound had strong binding ability with hub genes. Regarding cell experiments, HQFLT had the ability to inhibit proliferation, block cell cycle, induce cell apoptosis, inhibit colony formation, and inhibit migration and invasion of gastric cancer cells. qRT-PCR and Western blot experiments confirmed that HQFLT could down-regulate the expression of hub genes and inhibit the activation of RAS-MER-ERK signaling pathway.
conclusionHQFLT inhibited the proliferation and metastasis of gastric cancer. The mechanism may involve the regulation of the RAS-MEK-ERK signaling pathway, with ICAM1 and VCAM1 being potential targets for targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.